Related Experiment Video

Updated: May 16, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

A novel strategy for modulation of MDSC to enhance cancer immunotherapy

Tomar Ghansah1

  • 1University of South Florida; Department of Molecular Medicine; Tampa, FL USA.

Oncoimmunology
|November 20, 2012
PubMed

Insights

SHIP-1 regulates myeloid-derived suppressor cells (MDSC) in pancreatic tumors. Targeting SHIP-1 may offer new treatments for MDSC-related cancers, including hematological malignancies and solid tumors.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Myeloid-derived suppressor cells (MDSC) are key regulators of anti-tumor immune responses.
  • Dysregulation of MDSC contributes to tumor progression and immune evasion in various cancers.

Purpose of the Study:

  • To investigate the role of SHIP-1 in pancreatic tumor development.
  • To determine the regulatory relationship between SHIP-1 and MDSC in the tumor microenvironment.

Main Methods:

  • Utilized a combination of in vitro and in vivo models of pancreatic cancer.
  • Employed techniques to assess MDSC populations and function.
  • Analyzed SHIP-1 expression and its impact on MDSC activity.

Main Results:

  • SHIP-1 was found to play a significant role in pancreatic tumor development.
  • SHIP-1 regulates the function and accumulation of MDSC within the tumor microenvironment.
  • Evidence suggests SHIP-1's involvement in suppressing anti-tumor immunity.

Conclusions:

  • SHIP-1 is a critical regulator of MDSC in pancreatic cancer.
  • Targeting SHIP-1 presents a potential therapeutic strategy for hematological malignancies and solid tumors associated with MDSC.
  • Further research into SHIP-1 as a therapeutic target is warranted.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...